BrightPath Biotherapeutics Co., Ltd.
Stock Price Chart
2026/08/24 UpdatedPrice Trend
2026/08/24 UpdatedPrice & Trading Details
2026/08/24 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥5M | ¥0M | ¥1M | ¥0M |
| Gross Profit | ¥3M | ¥0M | ¥1M | ¥0M |
| Operating Income | -¥1,467M | -¥1,155M | -¥1,161M | -¥1,295M |
| Pretax Income | -¥1,484M | -¥1,155M | -¥1,161M | -¥1,295M |
| Net Income | -¥1,486M | -¥1,168M | -¥1,151M | -¥1,305M |
| EPS | -¥24.90 | -¥18.21 | -¥14.12 | -¥11.70 |
| Operating Margin | -27,785.21% | -1,604,276.39% | -102,464.08% | -1,541,667.86% |
| Balance Sheet | ||||
| Total Assets | ¥1,701M | ¥1,230M | ¥1,121M | ¥2,605M |
| Total Equity | ¥1,568M | ¥979M | ¥925M | ¥2,368M |
| Total Liabilities | ¥134M | ¥251M | ¥196M | ¥236M |
| Cash | ¥1,531M | ¥1,057M | ¥810M | ¥2,156M |
| Interest-bearing Debt | ¥0M | ¥113M | ¥25M | ¥0M |
| Equity Ratio | 92.13% | 79.58% | 82.54% | 90.92% |
| D/E Ratio | 0.00 | 0.11 | 0.03 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,204M | -¥1,157M | -¥1,250M | -¥1,366M |
| Investing CF | -¥2M | -¥8M | -¥1M | -¥2M |
| Financing CF | ¥432M | ¥691M | ¥1,005M | ¥2,714M |
| Free CF | -¥1,206M | -¥1,165M | -¥1,252M | -¥1,366M |
| Efficiency | ||||
| ROE | -94.77% | -119.32% | -124.45% | -55.10% |
| ROA | -87.32% | -94.95% | -102.73% | -50.10% |
Latest IR Information
-
Notice on FDA IND Acceptance as of August 3, 2026
announces acceptance of FDA IND for BP2202. Enables US Phase I clinical trial initiation for iPSC-derived BCMA CAR-NKT cell therapy, aiming to administer the first patient within the year. Impact on fiscal year ending March 2027 is unknown, but advancement...
Read more -
Notice of IND Submission to the U.S. FDA Related to BP2202
Read more -
Matters Related to Business Plans and Growth Potential
Read more -
Notice Regarding Resignation of Our Director
Read more
Latest News (5 items)
Company Information
About
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.
